Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
about
Pharmacological therapies for maintenance treatments of opium dependenceThe Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature2012 Update in addiction medicine for the generalistThe globalization of addiction research: capacity-building mechanisms and selected examplesCurrent and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.Alcohol use in opioid agonist treatmentUse of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary careRetention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisonersUpdate on Barriers to Pharmacotherapy for Opioid Use Disorders.Alcohol and Opioid Use Disorder in Older Adults: Neglected and Treatable Illnesses.Opioid Use Disorders.Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.Extended-release naltrexone opioid treatment at jail reentry (XOR)Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid DependenceEthical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceA randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.Advances in opioid antagonist treatment for opioid addiction.Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian FederationA comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients.Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependenceDesign, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivityValidation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS)Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions.Heavy alcohol use and suicidal behavior among people who use illicit drugs: A cohort studyTreating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomesCost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid DependenceDouble jeopardy--drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trialBaseline characteristics of patients predicting suitability for rapid naltrexone induction.Drug use patterns predict risk of non-fatal overdose among street-involved youth in a Canadian setting.The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
P2860
Q24201615-53AC7452-6072-4076-BF91-1346D71F04FDQ26741943-42CF7D17-86F9-4285-87D0-507150514517Q26864774-EA6D3AAC-457A-4C38-85E8-45544E547633Q27016126-DF5306D3-A021-4870-ACD0-C035327100DDQ27692554-3FA06574-034D-462E-BB33-A4918AEB74A4Q28073797-12B3CAEE-A3B1-47A1-B7F4-629D0C9568A1Q28081029-21EE3F99-7518-46B6-8968-82246763A05FQ28729018-8B5CDF52-9BC9-4E7F-90E3-CB9B1C27601CQ30234408-D6338764-1763-4A4B-9086-614FE3F7C59FQ30248638-C9FA5D73-CCA4-4483-88C4-27CF8B7E9C7FQ30249393-087AD41B-E514-4798-9CB2-5A1FAD388060Q30252443-C244A6E5-D9C9-4809-9ADF-CC056D3F8378Q30277067-3CA07826-C653-41CC-B71E-B43DF949B24BQ30300924-CA2E9A77-21D0-4FA4-AFA4-9BD5A08372A2Q33582025-C64E7F3E-04E2-4198-BEBD-4D101882E998Q33702350-B230D8BC-B41B-4CB8-8DE2-879F82A42906Q33755501-FD8BC78B-4687-4559-8729-F055BECC97B9Q33760413-6BC513C4-21B3-488A-BCB3-0703DF4F6743Q33783250-77090537-96D5-4306-A4EA-ABA218B1652BQ34040286-DA84EB3D-40F3-4A57-846C-3419D448FBFEQ34262649-BB96C8E6-340D-4975-A4F5-9CC60165EB08Q34458599-99E118C5-2A7B-4FCB-BC80-EA038A1FF25AQ34503746-5C56C1DC-F9A6-41CA-B851-38A2FF0F8DBAQ34615450-98657179-8DB0-4746-91B8-0FEDA17EFAD4Q34817072-7BA2E37A-CD24-4A21-9560-387DA92428ECQ35090939-8444C5ED-F5F1-40AF-AC85-EEEA387A178EQ35161399-FCC0EAC4-11E6-4D12-96E6-553C6C0506B4Q35216655-B06C2706-172B-40E1-A1F9-C3BB1BEE99D0Q35618756-5C1A562E-C419-4403-96FF-F32B1056C3DCQ35633106-E221BE05-B7F3-4BF6-AE59-04F14EEA55CFQ35646342-87525485-B5F6-469E-8C84-AF1F322045ABQ35660921-49B79CFA-8B2D-4C8C-AE68-ADADFD789E85Q35670689-21FD1F90-DAE5-4080-B993-A904BB7A8679Q35712988-869C4800-9551-4D49-A687-ECBEFEAC5518Q35751878-B56D7EF9-CB81-4882-86EF-6FF37B560CF0Q35818263-B40E6E8D-C75F-4526-A472-D839B41DF752Q35834292-90CEEA21-218C-4303-946C-C7F00A87AC85Q35875932-D05BAF64-D8A2-4A28-98B0-14BDE7DB0734Q35952033-EEC68659-1279-4DC9-8D58-2BDBBF895F58Q36001217-26C4AFCD-AFAD-45AD-A6A0-D039AF2DE65A
P2860
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Injectable extended-release na ...... multicentre randomised trial.
@en
Injectable extended-release na ...... multicentre randomised trial.
@nl
type
label
Injectable extended-release na ...... multicentre randomised trial.
@en
Injectable extended-release na ...... multicentre randomised trial.
@nl
prefLabel
Injectable extended-release na ...... multicentre randomised trial.
@en
Injectable extended-release na ...... multicentre randomised trial.
@nl
P2093
P921
P1433
P1476
Injectable extended-release na ...... multicentre randomised trial.
@en
P2093
Ari Illeperuma
Bernard L Silverman
David R Gastfriend
Edward V Nunes
Evgeny Krupitsky
Walter Ling
P304
P356
10.1016/S0140-6736(11)60358-9
P407
P577
2011-04-01T00:00:00Z